

Aldoxorubicin

Catalog No: tcsc1186



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1361644-26-9

Formula:

$C_{37}H_{42}N_4O_{13}$

Pathway:

Cell Cycle/DNA Damage;Antibody-drug Conjugate/ADC Related

Target:

Topoisomerase;ADC Cytotoxin

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

INNO-206;DOXO-EMCH

Observed Molecular Weight:

750.75


Product Description

Aldoxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.

IC50 & Target: Topoisomerase II^[4]

In Vitro: Aldoxorubicin (INNO-206) (0.27 to 2.16 μ M) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion^[1].

In Vivo: Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAG κ -1A tumor^[1]. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study^[2]. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!